very nice and very detail write up, tq.

Manufacturing (Manufacturing Excellence)
Our manufacturing facilities comply with the current Good Manufacturing Practice (“cGMP”) requirements of
Pharmaceutical Inspection Co-operation Scheme (“PIC/S”) and quality management system which is certified to the
standards of ISO 9001. Currently, we are working towards achieving ISO 17025 accreditation for our quality control
laboratary to be competent to carry out tests or calibration.
The Metered Dosage Inhaler Line (“MDI Line”) and the Pre-filled Syringe Manufacturing Line (“PFS Line”), a pioneer
initiative in Malaysia, has been inspected and approved by National Pharmaceutical Regulatory Agency (“NPRA”)
during the financial year under review. Both lines, with a built-up area of 351 square metres (MDI Line) and 625
square metres (PFS Line) are in compliance with the principles of Good Manufacturing Practice (“GMP”). Vaxcel
Granisetron 1mg/ml Injection Prefilled Syringe, our first approved PFS product will be launched soon in the market.
As for MDI, two (2) products are currently undergoing registration process. Approval of these lines will increase our
manufacturing capability via enhanced automation and expand our product portfolio.
The Group is optimistic that with our infrastructure, sufficient capacity and resources, we will herald more opportunities
to provide contract manufacturing services as well as tender and export supply in the future. extract FROM KOTRA annual report

https://www.perretica.com/marketsreview/week-30-2020

direct selling can attract a lot of jobless people. business sure increase . healthcare products is in good demand now.

cni selling health care products ???

more youngster will join CNI

FYI . I follow the crowd and bought 2 box of glove which contribute the increase in the demand of glove , but until today none has been use.

Why Munchy , why Kheesan ? Hwa Tai seems very cheap takeover target.
lets wait and see .

price of pharmaniaga keep down trend .

Bright debt free company. cash and bank balance 44.5 million ie rm 0.21per share

should take a look on kotra pharma (0002). It's cash flow and profit keep improving.

TPC so good profit but can't move

any good news in the report ?

DESINI. the next bumi giant

will icapital increase the share since it is so cheap ?

after velesto , next will be sapnrg

2016 short term loan only 348m . now I billion ???

dayang short term loan 1Billion ???

moving

asset value very strong

Sasbadi result good

dialog 5.6B ,astro 5.21B ,sunway 4.9B misc 4.46B , rhb bank 4.01B .pmetal 3.8B. who say 4B not a good counter

Rashid Hussain is the substantial shareholder of Pworth .Good,Good,Good

umwog overtake sapnrg to be leader in O&G sector

fly !!! another china counter

the new O&G leader . UMWOG

all 7 rigs of UMWOG are utilize by sept 2017. Only 2 rigs utilized in 2016. must buy because revenue will increase.

0.4 going to clear

bright . turnover improve. production run again

warrant in the money .can buy ?

45 cent dividend ?

still do gold mining ?

what is the definition used to define net cash for the above company ?can please explain .tq

siew k w is also shareholder of ancomlb

hope can get perdana share

under value stock. why price still so low?

leweco up . pworth up . cymao ?????

proposed 10 cent dividend

should sell phamaniaga and switch to kotra pharma or ccmbio

price and volumn increase . any good news?

if annualise, eps only 2 cent . P/E 33 times .

today closing hopefully 1.03

rm 1 touch

warrant premium too high

uplift from PN17 soon

any good news?

should buy mother share or warrant?

woh! warrant new conversion price adjusted to 0.85. so buy mother share or warrant ???

The Purchaser, CJ Korea Express Asia Pte Ltd, is a member company of CJ Korea
Express Corporation (“CJKX”), the largest logistics provider in Korea with a diversified
business portfolio offering integrated logistics solutions to both local and global
customers. CJKX, which is listed on the Korea Exchange, has a market capitalization of
4.5 trillion won (approximately USD4.1 billion) and global revenues of 5.1 trillion won
(approximately USD4.6 billion) for financial year ended 31 December 2015. CIMB
Investment Bank Berhad is the financial adviser to CJKX for this transaction

try take a look at shareholder no 18 and no 30 in 2015 annual report